Bio-Path Holdings, Inc. (BPTH)
| Market Cap | 16.17K -97.4% |
| Revenue (ttm) | n/a |
| Net Income | -4.13M |
| EPS | -0.30 |
| Shares Out | 53.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290 |
| Open | 0.0003 |
| Previous Close | 0.0006 |
| Day's Range | 0.0003 - 0.0003 |
| 52-Week Range | 0.0001 - 0.1134 |
| Beta | -0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About Bio-Path Holdings
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body’s enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company’s lead drug candidate is the Prexigebersen (BP1001), which is in phase ... [Read more]
Financial Performance
Financial StatementsNews
Bio-Path Holdings Quarterly report: Q1 2026
Bio-Path Holdings has published its Q1 2026 quarterly earnings report on May 20, 2026.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Bio-Path (BPTH), 159.19% surge in interest Alpha Cognitio...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: AIM ImmunoTech (AIM), 1,803.08% surge in interest Bio-Pat...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Bio-Path (BPTH), 143.53% surge in interest Pipeline and k...
Bio-Path Holdings Quarterly report: Q3 2025
Bio-Path Holdings has published its Q3 2025 quarterly earnings report on January 13, 2026.
Bio-Path Holdings Quarterly report: Q2 2025
Bio-Path Holdings has published its Q2 2025 quarterly earnings report on August 14, 2025.
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25
Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdi...
Bio-Path price target lowered to $2 from $9 at Roth Capital
Roth Capital lowered the firm’s price target on Bio-Path (BPTH) to $2 from $9 and keeps a Buy rating on the shares after the company updated its clinical pipeline progress.
Bio-Path provides highlights from clinical, operational update
Bio-Path (BPTH) Holdings announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accesse...
Bio-Path Holdings Provides Clinical and Operational Update
Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Li...
Bio-Path Holdings Transcript: Status Update
DNAbilize technology enables high-dose, non-toxic delivery of antisense DNA drugs, with clinical progress in AML, solid tumors, and metabolic diseases. Key candidates show durable remissions and promising preclinical results, with several programs nearing IND filings and out-licensing opportunities.
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025
HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfo...
Bio-Path Holdings Quarterly report: Q1 2025
Bio-Path Holdings has published its Q1 2025 quarterly earnings report on May 15, 2025.
Bio-Path achieves third milestone from preclinical studies of BP1001-A
Bio-Path (BPTH) Holdings reported the achievement of a third milestone from recent preclinical studies of BP1001-A that provide additional support for its potential as a treatment for obesity. These s...
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells
Bio-Path price target lowered to $9 from $12 at Roth MKM
Roth MKM lowered the firm’s price target on Bio-Path (BPTH) to $9 from $12 and keeps a Buy rating on the shares. The company ended Q4 with $1.2M in cash,…
Bio-Path Holdings Earnings release: Q4 2024
Bio-Path Holdings released its Q4 2024 earnings on March 28, 2025, summarizing the period's financial results.
Bio-Path Holdings Annual report: Q4 2024
Bio-Path Holdings has published its Q4 2024 annual report on March 28, 2025.
Bio-Path Holdings Reports Full Year 2024 Financial Results
HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a por...
Bio-Path reports results from preclinical studies of BP1001-A
Bio-Path (BPTH) Holdings reported results from recent preclinical studies of BP1001-A that support its potential as a treatment for obesity. In these studies, BP1001-A attenuated fatty acid-induced in...
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models Recent Pre-Clin...
Bio-Path receives new patents for P-ethoxy nucleic acids
Bio-Path (BPTH) announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on the extent of its global intellectual property portfolio. Bio-Path received...
Bio-Path provides key clinical updates on BP1001-A, AML
Bio-Path (BPTH) Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the Company’s ongoing P...
Bio-Path Holdings Provides Key Clinical Updates
First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease
Bio-Path announces BP1002 trial advances to higher dose cohort
Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of refractory/relapsed acute myeloid leukemia, including venetoclax-resistan...